Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

This study is testing a new combination of drugs — SHR-8068 (a targeted therapy) with adebrelimab (an immunotherapy) and other anti-cancer medications — for people with advanced kidney cancer that cannot be removed by surgery or has spread. **You may be eligible if...** - You are 18 to 75 years old - You have confirmed advanced or metastatic clear cell renal cell carcinoma (the most common type of kidney cancer) - You are in good physical condition (ECOG score 0 or 1) with an expected survival of at least 3 months - You have not previously used any drugs that target the HIF pathway - You have at least one measurable tumor per imaging criteria - You can provide a tumor tissue sample **You may NOT be eligible if...** - You have previously received immunotherapy, chemotherapy, or targeted therapy for this cancer within the past 4 weeks - You have previously used HIF inhibitor drugs - Your organ function (kidneys, liver, bone marrow) does not meet required levels Talk to your doctor to see if this trial is right for you.